Published in Immunotherapy Weekly, November 30th, 2005
"The precise mechanisms responsible for the failure of intrahepatic HCV-specific CD8+ T cells to control the virus during persistent infection have not been fully defined," wrote H.C. Spangenberg and colleagues, University of Freiburg Hospital.
"We therefore studied the CD8+ T-cell response in 27 HILA-A2-positive patients using four previously well-defined HI-A-A2-restricted HCV epitopes. The corresponding HCV sequences were determined in several patients and compared with the intrahepatic HCV-specific CD8+ T-cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2005-11-30)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.